Chemotherapy options for blastic plasmacytoid dendritic cell neoplasm Review

  


Authors: Haddadin, M.; Taylor, J.
Review Title: Chemotherapy options for blastic plasmacytoid dendritic cell neoplasm
Abstract: BPDCN is ultimately a bone marrow disease requiring induction-type eradication therapy followed by hematopoietic stem cell transplant (HSCT) to achieve long-lasting remissions or cure. Various regimens have been applied to this disease with varying success. A cumulative review of the literature suggests more intense regimens have greater efficacy with acute lymphoblastic leukemia regimens preferred to acute myeloid leukemia regimens. This approach benefits fit patients who are eligible for HSCT; however, most BPDCN patients require other treatment options. The recent FDA approval of the CD123-targeted agent tagraxofusp provides a novel therapeutic alternative to traditional chemotherapy but with potential toxicities. © 2020 Elsevier Inc.
Keywords: chemotherapy; induction; bpdcn; low-intensity
Journal Title: Hematology/Oncology Clinics of North America
Volume: 34
Issue: 3
ISSN: 0889-8588
Publisher: Elsevier Inc.  
Date Published: 2020-06-01
Start Page: 539
End Page: 552
Language: English
DOI: 10.1016/j.hoc.2020.01.011
PROVIDER: scopus
PUBMED: 32336418
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85081753233&doi=10.1016%2fj.hoc.2020.01.011&partnerID=40&md5=3b624ce4f56405c927ae8864faa81ecc
Notes: Review -- Export Date: 1 May 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Justin Taylor
    51 Taylor
  2. Michael Marwan Haddadin
    8 Haddadin
Related MSK Work